InvestorsHub Logo
Followers 1329
Posts 250614
Boards Moderated 53
Alias Born 12/07/2009

Re: None

Wednesday, 10/17/2018 1:19:24 PM

Wednesday, October 17, 2018 1:19:24 PM

Post# of 118421
$RGBP President and Chief Scientific Officer Harry Lander, Ph.D., MBA, says, "We have identified a handful of compounds representing three different structural classes that inhibit NR2F6 in our primary screening assay." https://seekingalpha.com/news/3386856-regen-biopharma-identifies-new-class-product-candidates?source=tweet $RGBP


ALL comments are In My Own OPINION. Please Use Your Own DD for Stock Trading.